Catalog No.
Product Name
Application
Product Information
Citations
-
Drug Impurity
Olmesartan impurity 15 is a characterized impurity associated with the antihypertensive agent olmesartan, which primarily targets the angiotensin II receptor. This compound is valuable for analytical research and quality control in pharmaceutical development, facilitating the assessment of olmesartan's purity and stability. Its detection is crucial for ensuring compliance with regulatory standards in drug manufacturing. -
Drug Impurity
Tamsulosin impurity 12 is a chemical impurity associated with Tamsulosin, an alpha-1 adrenergic antagonist primarily used for the treatment of benign prostatic hyperplasia. This impurity is critical for assessing the purity and quality of pharmaceutical formulations containing Tamsulosin. It serves as an important reference standard in drug development, stability studies, and quality control processes. -
Drug Impurity
Ticagrelor impurity 14 is a drug impurity associated with Ticagrelor, a medication primarily used as an antiplatelet agent. This impurity can be utilized in quality control and analytical studies for pharmaceutical research to ensure the purity and safety of Ticagrelor formulations. Its characterization may aid in understanding the stability and metabolic pathways of the parent compound in various biological systems. -
Drug Impurity
Fluphenazine decanoate impurity 8 is a known impurity associated with Fluphenazine decanoate, an antipsychotic medication primarily targeting dopamine receptors. This compound can be utilized in analytical research to evaluate the purity of pharmaceutical formulations and support drug development processes. Its presence may affect pharmacokinetics and pharmacodynamics, making it essential for quality control and safety assessments in therapeutic applications. -
Drug Impurity
Dabigatran impurity 3 is a chemical impurity associated with the anticoagulant Dabigatran. Its presence is significant for analytical studies and quality control during pharmaceutical development. This reagent is essential for assessing the purity of Dabigatran formulations and for conducting stability studies in drug development. -
Drug Impurity
Salmeterol impurity 2, also known as Salmeterol impurity D, is a known impurity associated with the β2-adrenergic agonist Salmeterol. Characterized by its structural variants, this impurity serves as an important reference standard in pharmaceutical research and development. Its analysis is critical for ensuring the purity and quality of Salmeterol formulations, contributing to safety and efficacy evaluations. -
Drug Impurity
Olmesartan impurity 7 is a known impurity associated with the angiotensin II receptor blocker, Olmesartan. This compound is utilized in the characterization and quality control of Olmesartan formulations. Its analysis is crucial for ensuring the purity and safety of pharmaceutical products in hypertension research. -
Drug Impurity
Everolimus impurity 15 is a byproduct of Everolimus, an mTOR inhibitor. It serves as a critical reference standard for analytical chemistry, particularly in the assessment of drug purity during the development and quality control of pharmaceutical formulations. This compound can aid in the identification of potential process-related impurities and support regulatory submissions for Everolimus-based therapies. -
Drug Impurity
Lamivudine impurity 3 is a recognized impurity associated with the antiviral compound Lamivudine. As a byproduct of the drug synthesis process, it is relevant for quality control and analytical purposes in drug formulation studies. This impurity can aid in the assessment of the purity and safety of Lamivudine formulations in pharmaceutical research and development. -
Drug Impurity
Fluphenazine decanoate impurity 11 is a known impurity of the antipsychotic medication Fluphenazine decanoate. This compound may be utilized in chemical research and quality control studies to assess the purity of Fluphenazine decanoate formulations. Understanding such impurities is crucial for the development and regulation of pharmaceutical products, as they may impact drug efficacy and safety. -
Drug Impurity
Atenolol impurity 2, also known as C-Desmethyl atenolol, is a significant impurity of the antihypertensive agent Atenolol. Its presence can affect the purity and efficacy of drug formulations. This compound is essential for quality control and analytical studies in pharmaceutical research, particularly in assessing the safety and effectiveness of Atenolol preparations. -
Drug Impurity
Methylprednisolone acetate impurity 6 is a chemical impurity associated with Methylprednisolone acetate. This compound is significant in the context of pharmaceutical quality control and toxicology studies. It serves as a reference standard for assessing the purity and stability of corticosteroid formulations in research and development processes. -
Drug Impurity
Tenofovir impurity 25 is a known impurity of Tenofovir, a nucleotide reverse transcriptase inhibitor used in the treatment of HIV infection. This compound serves as an important reference standard for quality control and analytical purposes in pharmaceutical research. Its characterization and quantification are essential for ensuring the purity and efficacy of Tenofovir formulations in compliance with regulatory standards. -
Drug Impurity
Levothyroxine impurity 12 is a recognized impurity associated with Levothyroxine, a synthetic form of the thyroid hormone thyroxine. This compound serves as a critical reference standard in pharmaceutical analysis to ensure the quality and safety of Levothyroxine formulations. Its characterization and quantification are essential for regulatory compliance and quality control during drug development and production processes. -
Drug Impurity
Budesonide impurity 87 is a known impurity associated with Budesonide, primarily studied for its relevance in pharmacological assessments and drug quality control. This compound can be used in research applications aimed at understanding the stability, safety, and efficacy of Budesonide formulations. It serves as a critical reference in the analysis of drug purity and compliance with regulatory standards. -
Drug Impurity
Amlodipine impurity 7, also known as 2-Carboxybenzoyl amlodipine, is a recognized impurity associated with Amlodipine. This compound serves as an important reference standard in the quality control and analytical assessment of Amlodipine formulations. Its characterization is essential for ensuring the purity and potency of pharmaceutical products containing Amlodipine. This impurity can be utilized in various research applications aimed at developing more effective drug formulations and improving overall drug safety. -
Drug Impurity
Escitalopram impurity 8 is a chemical impurity associated with the selective serotonin reuptake inhibitor (SSRI) escitalopram. This impurity serves as a vital quality control parameter in pharmaceutical development and analytical studies of escitalopram, aiding in the identification and quantification of impurities during drug formulation processes. Its presence must be monitored to ensure the safety, efficacy, and regulatory compliance of escitalopram-containing medications. -
Drug Impurity
Buspirone impurity 1 is a chemical impurity associated with the pharmacological agent Buspirone. It serves as a reference standard for quality control and analytical studies in drug development. This impurity is significant for assessing the purity and stability of Buspirone formulations in both research and clinical applications. -
Drug Impurity
Apixaban impurity 39 is a chemical impurity associated with Apixaban, a direct oral anticoagulant that selectively inhibits Factor Xa. The presence of this impurity is important for quality control during the synthesis and formulation of Apixaban. Researchers may utilize this reagent in pharmacokinetic studies, stability testing, and impurity profiling to ensure the safety and efficacy of formulations containing Apixaban. -
Drug Impurity
Edoxaban Impurity 49 is a chemical impurity associated with Edoxaban, a direct factor Xa inhibitor. This impurity is important for analytical research and development, providing insight into the characterization and quality assessment of Edoxaban. It can be utilized in stability studies and impurity profiling to ensure the integrity and efficacy of pharmaceutical formulations. -
Drug Impurity
Nicodil impurity 1 is a chemical impurity associated with Nicodil, which targets specific pharmacological pathways. This reagent is primarily utilized in the analytical assessment of drug purity and stability, providing critical insights into the compound's safety and efficacy. Its presence may affect the overall profile of Nicodil, making it essential for rigorous quality control and regulatory compliance in pharmaceutical research. -
Drug Impurity
Donepezil impurity 26 is a chemical impurity associated with the synthesis of Donepezil. It serves as a reference standard for quality control and analytical testing during the production of Donepezil. This compound is essential for evaluating the purity, stability, and efficacy of Donepezil formulations, ensuring compliance with regulatory standards in pharmaceutical development. -
Drug Impurity
Quetiapine impurity 15 is identified as a minor structural variant of Quetiapine, primarily classified as a drug impurity. This compound is utilized in analytical chemistry for the characterization and quantification of drug formulations. Its presence can influence the overall efficacy and safety profiles of pharmaceutical products, making it significant for quality control and regulatory compliance in drug development studies. -
Drug Impurity
Moxifloxacin impurity 7 is a drug impurity associated with the antibiotic moxifloxacin. It serves as a reference standard for quality control and analytical testing in pharmaceutical research and development. Characterizing such impurities is essential for ensuring drug safety and efficacy, contributing to the overall assessment of moxifloxacin formulations. -
Drug Intermediate
5-(2-Aminopyridyl)amide oxime is a synthetic intermediate primarily used in pharmaceutical synthesis. This compound serves as a versatile building block in the development of bioactive molecules and pharmaceuticals. Its unique chemical structure allows for the exploration of various medicinal chemistry applications, facilitating the design and optimization of potential therapeutic agents. -
Drug Impurity
Sildenafil Impurity 2 is a known impurity associated with Sildenafil. This compound serves as an important reference material for quality control and analytical studies in pharmaceutical research. Its detection and characterization are critical for ensuring the purity and regulatory compliance of Sildenafil formulations. Researchers may utilize this impurity in studies focused on pharmaceutical development and safety evaluation. -
Drug Impurity
Edoxaban impurity 3 is a chemical impurity related to the anticoagulant Edoxaban, primarily used for monitoring drug quality and stability. Its presence in formulations can impact the pharmacokinetics and safety profile of the drug. This compound is essential for analytical method development, quality control, and regulatory compliance within pharmaceutical research. -
Drug Impurity
Tamsulosin impurity 16 is a known impurity of Tamsulosin, primarily studied for its effects in pharmaceutical research and quality control. This compound may be utilized to assess the purity of Tamsulosin formulations and to better understand the implications of drug impurities on pharmacological activity. Its analysis contributes to ensuring compliance with regulatory standards and optimizing drug safety and efficacy. -
Drug Impurity
Sildenafil Impurity 15 is a defined impurity associated with the pharmaceutical compound Sildenafil. Characterized by its structural variations, this compound is utilized primarily in drug development and quality control studies to ensure the purity of Sildenafil formulations. Its analysis is essential for regulatory compliance and enhances the understanding of the stability and efficacy of Sildenafil-related products. -
Drug Impurity
(3R,5S,E)-3,5-Dihydroxy-7-(4-isopropyl-2-(N-methylmethylsulfonamido)-6-phenylpyrimidin-5-yl)hept-6-enoic acid is a known impurity of Rosuvastatin, a widely-used cholesterol-lowering medication. This compound serves as a vital reference standard in the analysis of Rosuvastatin formulations, helping to ensure consistency and compliance in pharmaceutical development. Its characterization is essential for researchers conducting quality control and stability studies within the drug manufacturing process. -
Drug Impurity
Dabigatran impurity 29, also known as Dabigatran impurity F, is a known impurity of the anticoagulant agent Dabigatran. This compound is utilized in quality control processes to assess the purity of Dabigatran formulations. Its presence is crucial for maintaining compliance with pharmaceutical standards and ensuring the safety and efficacy of the drug in clinical applications. -
Drug Impurity
Dabigatran impurity 8 is a characterized impurity of the anticoagulant Dabigatran, primarily functioning as a direct thrombin inhibitor. This compound is critical for analytical and quality control studies, enabling the assessment of the purity and safety of Dabigatran formulations. Its identification and quantification are essential in the regulatory and development processes of pharmaceutical products containing Dabigatran. -
Drug Impurity
Trazodone impurity 9 is a known impurity formed during the synthesis of Trazodone, a serotonin modulator. This compound may be used in the assessment of drug purity and quality control in pharmaceutical formulations. Its presence and concentration can provide insights into the synthesis process and the overall stability of the active pharmaceutical ingredient. -
Drug Impurity
Ranitidine impurity 3, also known as Ranitidine impurity J, serves as an impurity associated with Ranitidine. This compound is primarily utilized in pharmaceutical research to assess the purity of Ranitidine formulations. Its analysis contributes to quality control and safety testing in drug development. -
Drug Impurity
Cinnarizine impurity 7 is a chemical impurity associated with the antihistamine agent Cinnarizine. As an analytical standard, it is crucial for quality control and compliance in pharmaceutical research and development. This compound aids in the identification and quantification of impurities in Cinnarizine formulations, facilitating studies on drug efficacy and safety. -
Drug Intermediate
2-(2-Pyridyl)-4-methyl-thiazole-5-carboxylic acid is a versatile synthetic intermediate with applications in pharmaceutical synthesis. This compound serves as a key building block in the development of biologically active molecules and can facilitate the exploration of novel therapeutic agents. Its structural properties make it particularly valuable for research in medicinal chemistry and drug discovery. -
Drug Impurity
Ramipril impurity 5 is a drug impurity of Ramipril, an angiotensin-converting enzyme (ACE) inhibitor. This compound is essential for analytical studies focused on the characterization and quantification of impurities in pharmaceutical formulations of Ramipril. Its identification aids in ensuring the purity and quality of drug products, contributing to regulatory compliance and safety assessments in pharmaceutical research. -
Drug Impurity
Sertraline impurity 3 is a byproduct of the selective serotonin reuptake inhibitor, Sertraline. This compound is relevant in the context of pharmaceutical quality control, specifically for assessing the purity and stability of Sertraline formulations. Its characterization aids in the identification and quantification of impurities, ensuring compliance with regulatory standards in drug development and manufacturing. -
Drug Impurity
Lifitegrast impurity 6 is a chemical impurity associated with Lifitegrast, an integrin antagonist. This compound serves as a reference standard for quality control and analytical studies in pharmaceutical research. Its characterization is essential for ensuring the purity and efficacy of Lifitegrast formulations in drug development and regulatory compliance. -
Drug Impurity
Dexmedetomidine impurity 7, also known as 1-Benzyl vinyl medetomidine, is a chemical impurity associated with Dexmedetomidine. This compound is useful for analytical purposes in pharmaceutical research, particularly in the assessment of drug purity and stability. It serves as a standard reference in the study of drug formulation and quality control, aiding in the evaluation of potential side effects and pharmacological profiles. -
Drug Impurity
Chlorthalidone impurity 1 is a known impurity associated with the thiazide-like diuretic agent chlorthalidone. This compound serves as a critical reference standard in drug characterization and quality control processes. Its identification and quantification are essential in ensuring the purity and compliance of chlorthalidone formulations within pharmaceutical research and development. -
Drug Impurity
Erythromycin impurity 2 is a noted impurity associated with Erythromycin. This compound is relevant in the study of drug quality and safety, particularly in pharmaceutical development and analysis. It serves as an important reference for evaluating the purity of erythromycin formulations and understanding the potential effects of impurities on drug efficacy and safety. -
Drug Impurity
Ondansetron impurity 3, also known as N-Desmethylondansetron, is a recognized impurity of the antiemetic drug Ondansetron. It serves as an important reference compound for quality control and analytical purposes in drug development. Researchers utilize this impurity to assess the purity, stability, and safety of Ondansetron formulations, as well as to study its metabolic pathways and pharmacological profiles. -
Drug Impurity
Ledipasvir impurity 55 is a known impurity associated with the antiviral agent Ledipasvir, which primarily targets the NS5A protein of the hepatitis C virus. This compound is crucial for the development and quality control of Ledipasvir formulations in pharmaceutical research, ensuring the efficacy and safety of antiviral therapies. It serves as a valuable reference standard in analytical studies and characterizes the purity of drug substances in pharmaceutical development. -
Drug Impurity
Azilsartan impurity 14 is a known impurity of the antihypertensive agent Azilsartan, primarily associated with its synthesis and quality control studies. This compound may be utilized for analytical purposes, including the characterization and quantification of Azilsartan in pharmaceutical formulations. Its presence can provide insights into synthetic pathways and contribute to the assessment of drug safety and efficacy profiles in research applications. -
Drug Impurity
Metoprolol impurity 15 is a characterized impurity of the beta-blocker Metoprolol. This compound is utilized primarily in quality control and analytical studies to assess the purity and stability of Metoprolol formulations. It serves as a reference standard for the identification and quantification of impurities in pharmaceutical research and development. -
Drug Impurity
Ranolazine impurity 8 is a chemical byproduct associated with Ranolazine, a drug primarily used for the treatment of chronic angina. This impurity can be utilized in quality control and analytical studies to ensure the purity of Ranolazine formulations. It serves as an important reference standard for researchers engaged in pharmaceutical development and regulatory compliance. -
Drug Impurity
6,6'-(1,4-Phenylenebis(oxy))bis(hexan-1-ol) is characterized as a drug impurity with potential implications in pharmaceutical development. This compound may influence drug stability, efficacy, and safety profiles during analytical assessments. Its role as an impurity can aid in the understanding of synthesis processes and help in the evaluation of product quality in drug formulation studies. -
Drug Impurity
Mirabegron impurity 7 is a chemical impurity associated with the synthesis of Mirabegron, a beta-3 adrenergic agonist. This impurity is useful for analytical purposes, particularly in the development and quality control of pharmaceutical formulations containing Mirabegron. It serves as a reference standard for assessing the purity and stability of the active pharmaceutical ingredient during research and development processes. -
Drug Impurity
Aripiprazole impurity 13 is a defined impurity of the antipsychotic agent Aripiprazole. This compound is primarily utilized for quality control and analytical purposes in pharmaceutical research, ensuring the safety and efficacy of Aripiprazole formulations. It serves as a critical reference standard for identification and quantification in drug development and regulatory compliance.
